Cisplatin News and Research

RSS

New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas

Childhood brainstem gliomas (BSGs) are rare but can be very difficult to treat successfully and they tend to have poor survival rates.

26 Sep 2007

BRCA1 gene plays significant role in non-small cell lung cancer

Barcelona, Spain: Researchers have found that the breast cancer susceptibility gene, BRCA1, plays a significant role in non-small cell lung cancer (NSCLC).

25 Sep 2007

Chemoradiation in advanced head and neck cancers

Advanced cancer in the head and neck is traditionally treated with surgery followed by radiotherapy.

17 Sep 2007

Avastin approved in Europe for advanced lung cancer

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.

26 Aug 2007

Cranberries, chemo and ovarian cancer

Compounds in cranberries may help improve the effectiveness of platinum drugs that are used in chemotherapy to fight ovarian cancer, researchers have found in a laboratory study that will be reported at the 234 th national meeting of the American Chemical Society.

22 Aug 2007

Age-related hearing loss very common

For many people, hearing loss is part of aging. Hearing loss affects approximately one-third of people over age 65. Among people age 75 and older, 40 percent to 50 percent experience hearing loss.

7 Aug 2007

High-dose chemotherapy and a stem cell transplant cures testicular cancer

Testicular cancer patients who do not respond to traditional therapy can be cured with high-dose chemotherapy and a stem cell transplant, according to an Indiana University School of Medicine report in the July 26 issue of the New England Journal of Medicine.

26 Jul 2007

New algorithm matches any tumor cells to best possible anti-cancer treatments

Cancer patients don't have time to waste. Many go through several different treatments, however, to find one that is more effective against their particular type of tumor.

24 Jul 2007

Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery.

16 Jul 2007

Bak protein's deadly double whammy

When a cell is seriously stressed, say by a heart attack, stroke or cancer, a protein called Bak just may set it up for suicide, researchers have found.

13 Jul 2007

Oncolytic viruses deliver a knockout punch to cancers

New scientific evidence is helping to build a compelling case for oncolytic viruses as a first-line and adjunctive treatment for many cancers.

11 May 2007

Diabetes drug rosiglitazone boosts power of platinum chemotherapy

A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber Cancer Institute report.

8 May 2007

Magnesium loss In patients given monoclonal antibodies

97% of patients with cancer treated with monoclonal antibodies—cetuximab, matuzumab, or panitumumab—that target the epidermal growth factor receptor (EGFR) have some degree of magnesium loss (hypomagnesaemia), according to a study published in the May issue of The Lancet Oncology.

2 May 2007

Why cisplatin kills breast cancer cells when other drugs fail

The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2.

20 Apr 2007

New research may help identify patients most likely to benefit from cisplatin treatment

Researchers at the Massachusetts General Hospital (MGH) Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors.

20 Apr 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007